Stock comparison
JOHNSON & JOHNSON is 326.8x more valuable than Trevi Therapeutics, Inc. by market capitalization ($664.95 B vs $2.03 B). Compare market value, revenue, profit, margins, filings, and source pages in one place.
Quick answer
JNJ is larger
JOHNSON & JOHNSON is 326.8x more valuable than Trevi Therapeutics, Inc. by market capitalization ($664.95 B vs $2.03 B).
Market value leader
JNJ
JOHNSON & JOHNSON is 326.8x more valuable than Trevi Therapeutics, Inc. by market capitalization ($664.95 B vs $2.03 B).
Profit leader
JNJ
TRVI: -$42.76M vs JNJ: $26.80B.
| Metric | TRVI | JNJ |
|---|---|---|
| Market cap | $2.03 B | $664.95 B |
| US-listed rank | #2076 | #17 |
| Revenue (latest FY) | - | $94.19B |
| Net income (latest FY) | -$42.76M | $26.80B |
| Net margin | - | 28.5% |
| P/E (trailing FY) | - | 24.8x |
| SEC filings | 524 | 1,004 |
Jump from this comparison into the underlying pages for market value, annual fundamentals, and company filing history.
Market cap uses refreshed market data. Revenue, net income, margins, and trailing fiscal-year P/E use annual company facts from filings. If a metric is missing, the source data did not have a clean recent annual value for that company.
JOHNSON & JOHNSON is 326.8x more valuable than Trevi Therapeutics, Inc. by market capitalization ($664.95 B vs $2.03 B).
Full pages: Trevi Therapeutics, Inc. and JOHNSON & JOHNSON, or browse the full rankings.